Filing Flows › GoodRx Holdings (GDRX) › Q1 2026 › vs Q1 2025
GoodRx Holdings (GDRX) Q1 2026 vs Q1 2025 (year over year)
GoodRx Holdings's revenue fell $9.0M (-4%) from $203M in Q1 2025 to $194M in Q1 2026. The biggest changes: Prescription transactions revenue −$35.2M (-24%); Pharma Direct revenue +$23.6M (+82%); Subscription revenue +$3.4M (+16%). Operating margin 7.2% against 11.5% (-4.3 pts).
GoodRx Holdings, Q1 2026: revenue $194M (-4% year over year), operating margin 7.2%, net earnings $1.2M, operating cash flow $11.8M. The chart draws each line against Q1 2025, the increases inside each band.
Margins
| Q1 2026 | Q1 2025 | Change | |
|---|---|---|---|
| Operating margin | 7.2% | 11.5% | -4.3 pts |
| Net margin | 0.6% | 5.4% | -4.8 pts |
| Free cash flow margin | 5.5% | 4.6% | +0.9 pts |
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Prescription transactions revenue | $114M | $149M | −$35.2M | -24% |
| Pharma Direct revenue | $52.2M | $28.6M | $23.6M | +82% |
| Subscription revenue | $24.4M | $21.0M | $3.4M | +16% |
| Other revenue | $3.7M | $4.4M | −$691K | -16% |
| Revenue | $194M | $203M | −$9.0M | -4% |
| Operating profit | $14.0M | $23.4M | −$9.4M | -40% |
| Costs & expenses | $180M | $180M | $407K | +0.2% |
| Pre-tax earnings | $5.6M | $16.7M | −$11.0M | -66% |
| Other expense, net | $8.4M | $6.7M | $1.7M | +25% |
| Cost of revenue | $20.2M | $13.4M | $6.8M | +51% |
| Research & development | $30.2M | $31.1M | −$965K | -3% |
| Sales & marketing | $81.1M | $84.5M | −$3.5M | -4% |
| General & admin | $26.8M | $29.6M | −$2.8M | -9% |
| Other operating costs | $21.8M | $20.9M | $880K | +4% |
| Net earnings | $1.2M | $11.1M | −$9.9M | -89% |
| Income tax | $4.5M | $5.6M | −$1.1M | -20% |
| Operating cash sources | $39.5M | $51.1M | −$11.7M | -23% |
| Depreciation & amortization | $21.8M | $20.9M | $880K | +4% |
| Share-based compensation | $16.5M | $19.2M | −$2.7M | -14% |
| Working capital & other | $27.6M | $41.7M | −$14.1M | -34% |
| Operating cash flow | $11.8M | $9.4M | $2.4M | +26% |
| Free cash flow (OCF − capex) | $10.7M | $9.3M | $1.4M | +15% |
| Capital expenditures | $1.1M | $142K | $994K | +700% |
Questions
How much did GoodRx Holdings's revenue grow year over year in Q1 2026?
GoodRx Holdings's revenue fell $9.0M (-4%) from $203M in Q1 2025 to $194M in Q1 2026.
What drove GoodRx Holdings's revenue change in Q1 2026?
Prescription transactions revenue −$35.2M (-24%); Pharma Direct revenue +$23.6M (+82%); Subscription revenue +$3.4M (+16%).